In patients receiving an AIT, their IgE levels did not change significantly during the observational period of 16 weeks, whereas significantly decreased IgE levels were detected at later timepoints in previous studies on AD patients receiving an AIT.58, 59. The gene discussed is IGHE; the disease is Alzheimer disease.